Browsing Tag
immune thrombocytopenia
5 posts
Gilead Sciences bets $2.2bn on immune reset with Ouro Medicines BCMAxCD3 bispecific acquisition
Gilead Sciences agrees to acquire Ouro Medicines for up to $2.175bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Read the full strategic analysis.
Takeda announces positive results for mezagitamab in Phase 2 ITP study
Takeda Pharmaceutical Company Limited has disclosed favorable top-line outcomes from a Phase 2, randomized, double-blind, placebo-controlled trial, assessing…
Oscotec reports positive results from cevidoplenib phase 2 trial in ITP
Oscotec has reported positive results from the phase 2 clinical trial of its SYK inhibitor cevidoplenib in patients…
Sobi begins avatrombopag phase 3 trial in immune thrombocytopenia in pediatrics
Swedish Orphan Biovitrum (Sobi) said that the first patient has been dosed with Doptelet (avatrombopag) in a phase…
FDA greenlights Amgen’s Nplate for pediatric immune thrombocytopenia
Amgen’s Nplate (romiplostim) has received US Food and Drug Administration (FDA) approval for treating pediatric patients with immune…